Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| EVA - Grupo Brasileiro de Tumores Ginecológicos | UNKNOWN |
| Roche Pharma AG | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to describe the socio-demographic, clinical pathological, quality of life and treatment characteristics of patients diagnosed with CC in Brazil.
The primary objective of this study is to describe the socio-demographic, clinical pathological, quality of life and treatment characteristics of patients diagnosed with cervix cancer (CC) in Brazil. Other specific objectives are:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Quality of Life Questionnaire (QLQ) | Behavioral | The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Cervical cancer module (EORTC QLQ-CX24) will be applied to all patients at 0, 3, 6, 12, 24, 36 months. |
| Measure | Description | Time Frame |
|---|---|---|
| Characterization of cervix cancer in the Brazilian female population | 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Socio-demographic characteristics of the female population diagnosed with CC | Month 0 (beginning of the study) | |
| Description of the method used to diagnose the brazillian female patients with cervix cancer | Screening tests (Papanicolaou test) or symptoms presented by patients |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients diagnosed with cervical cancer in 1-year period (recently diagnosed IB to IIA high risk or IIB-IVB or recurrent disease - FIGO stages) at the participating sites will be included in the study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gustavo Werutsky, MD | Latin American Cooperative Oncology Group | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fundação Centro de Controle do Câncer do Estado do Amazonas | Manaus | Amazonas | Brazil | |||
| CRIO |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21296855 | Background | Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. | |
| 18945407 | Background | Munoz N, Franco EL, Herrero R, Andrus JK, de Quadros C, Goldie SJ, Bosch FX. Recommendations for cervical cancer prevention in Latin America and the Caribbean. Vaccine. 2008 Aug 19;26 Suppl 11:L96-L107. doi: 10.1016/j.vaccine.2008.05.062. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Month 0 |
| The clinical and pathological characteristics of cervix cancer in brazilian female patients | Month 0 |
| Type of treatment assessed in patients with CC | Radiotherapy, Chemotherapy and/or Surgery | Month 0, 3, 6,12, 24 and 36 |
| Number of patients with disease survival | Month 3, 6, 12, 24 and 36 |
| Number of patients with progression survival | Month 3, 6, 12, 24 and 36 |
| Number of patients with overall survival | Month 3, 6, 12, 24 and 36 |
| Number of patients with disease overall survival | Month 3, 6, 12, 24 and 36 |
| Type and description of the indicated treatment after the diagnosis of cervix cancer in brazilian female patients | Month 0, 3, 6,12, 24 and 36 |
| Duration of treatment after the diagnosis of cervix cancer | Month 0, 3, 6,12, 24 and 36 |
| Description of adverse effects of the cervix cancer treatment | Month 0, 3, 6,12, 24 and 36 |
| Number of adverse effects of the cervix cancer treatment | Month 0, 3, 6,12, 24 and 36 |
| Type of clinical outcomes of the patients with cervix cancer in Brazil | Month 0, 3, 6,12, 24 and 36 |
| Fortaleza |
| Ceará |
| Brazil |
| Clínica AMO | Salvador | Estado de Bahia | Brazil |
| HU Walter Cantídeo | Ceará | Fortaleza | CE | Brazil |
| Hospital Alderona Bello | São Luís | Maranhão | Brazil |
| UFMG | Belo Horizonte | Minas Gerais | Brazil |
| Hospital Erasto Gaertner | Curitiba | Paraná | Brazil |
| IMIP | Recife | Pernambuco | Brazil |
| Hospital São Vicente de Paulo | Passo Fundo | Rio Grande do Sul | Brazil |
| CPO - Hsl/Pucrs | Porto Alegre | Rio Grande do Sul | Brazil |
| Hospital Geral de Roraima | Boa Vista | Roraima | Brazil |
| CEPON | Florianópolis | Santa Catarina | Brazil |
| Centro de Novos Tratamentos Litoral - Itajaí | Itajaí | Santa Catarina | Brazil |
| INCA | Rio de Janeiro | Brazil |
| Hospital São José | São Paulo | Brazil |
| Instituto Brasileiro de Controle do Câncer - IBCC | São Paulo | Brazil |
| 21220591 | Background | Hellner K, Munger K. Human papillomaviruses as therapeutic targets in human cancer. J Clin Oncol. 2011 May 1;29(13):1785-94. doi: 10.1200/JCO.2010.28.2186. Epub 2011 Jan 10. |
| 23827721 | Background | Martinez-Mesa J, Werutsky G, Campani RB, Wehrmeister FC, Barrios CH. Inequalities in Pap smear screening for cervical cancer in Brazil. Prev Med. 2013 Oct;57(4):366-71. doi: 10.1016/j.ypmed.2013.06.026. Epub 2013 Jul 1. |
| 24449243 | Background | Zuliani AC, Esteves SC, Teixeira LC, Teixeira JC, de Souza GA, Sarian LO. Concomitant cisplatin plus radiotherapy and high-dose-rate brachytherapy versus radiotherapy alone for stage IIIB epidermoid cervical cancer: a randomized controlled trial. J Clin Oncol. 2014 Feb 20;32(6):542-7. doi: 10.1200/JCO.2013.50.1205. Epub 2014 Jan 21. |
| 11844818 | Background | Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, MacLean G, Souhami L, Stuart G, Tu D. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002 Feb 15;20(4):966-72. doi: 10.1200/JCO.2002.20.4.966. |
| ID | Term |
|---|---|
| D002583 | Uterine Cervical Neoplasms |
| ID | Term |
|---|---|
| D014594 | Uterine Neoplasms |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D002577 | Uterine Cervical Diseases |
| D014591 | Uterine Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
Not provided
Not provided